BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 36252564)

  • 1. Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.
    Church C; Pulliam T; Longino N; Park SY; Smythe KS; Makarov V; Riaz N; Jing L; Amezquita R; Campbell JS; Gottardo R; Pierce RH; Choi J; Chan TA; Koelle DM; Nghiem P
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36252564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.
    Miller NJ; Church CD; Fling SP; Kulikauskas R; Ramchurren N; Shinohara MM; Kluger HM; Bhatia S; Lundgren L; Cheever MA; Topalian SL; Nghiem P
    J Immunother Cancer; 2018 Nov; 6(1):131. PubMed ID: 30482247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Merkel cell polyomavirus-specific CD8⁺ and CD4⁺ T-cell responses identified in Merkel cell carcinomas and blood.
    Iyer JG; Afanasiev OK; McClurkan C; Paulson K; Nagase K; Jing L; Marshak JO; Dong L; Carter J; Lai I; Farrar E; Byrd D; Galloway D; Yee C; Koelle DM; Nghiem P
    Clin Cancer Res; 2011 Nov; 17(21):6671-80. PubMed ID: 21908576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
    Goh G; Walradt T; Markarov V; Blom A; Riaz N; Doumani R; Stafstrom K; Moshiri A; Yelistratova L; Levinsohn J; Chan TA; Nghiem P; Lifton RP; Choi J
    Oncotarget; 2016 Jan; 7(3):3403-15. PubMed ID: 26655088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into anti-tumor immunity
    Jani S; Church CD; Nghiem P
    Front Immunol; 2023; 14():1172913. PubMed ID: 37287968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers.
    Afanasiev OK; Yelistratova L; Miller N; Nagase K; Paulson K; Iyer JG; Ibrani D; Koelle DM; Nghiem P
    Clin Cancer Res; 2013 Oct; 19(19):5351-60. PubMed ID: 23922299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition.
    Buchta Rosean C; Leyder EC; Hamilton J; Carter JJ; Galloway DA; Koelle DM; Nghiem P; Heiland T
    Front Immunol; 2023; 14():1253568. PubMed ID: 37711623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.
    Colunga A; Pulliam T; Nghiem P
    Clin Cancer Res; 2018 May; 24(9):2035-2043. PubMed ID: 29217527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
    Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
    J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
    Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
    Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications.
    Walsh NM; Castonguay MC; Carter MD; Pasternak S; Ly TY; Doucette S; Hanly JG; Saggini A; Cerroni L
    Am J Dermatopathol; 2019 Nov; 41(11):819-825. PubMed ID: 31634167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma.
    Feldmeyer L; Hudgens CW; Ray-Lyons G; Nagarajan P; Aung PP; Curry JL; Torres-Cabala CA; Mino B; Rodriguez-Canales J; Reuben A; Chen PL; Ko JS; Billings SD; Bassett RL; Wistuba II; Cooper ZA; Prieto VG; Wargo JA; Tetzlaff MT
    Clin Cancer Res; 2016 Nov; 22(22):5553-5563. PubMed ID: 27166398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.
    Lipson EJ; Vincent JG; Loyo M; Kagohara LT; Luber BS; Wang H; Xu H; Nayar SK; Wang TS; Sidransky D; Anders RA; Topalian SL; Taube JM
    Cancer Immunol Res; 2013 Jul; 1(1):54-63. PubMed ID: 24416729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma.
    Pulliam T; Jani S; Jing L; Ryu H; Jojic A; Shasha C; Zhang J; Kulikauskas R; Church C; Garnett-Benson C; Gooley T; Chapuis A; Paulson K; Smith KN; Pardoll DM; Newell EW; Koelle DM; Topalian SL; Nghiem P
    Cell Rep Med; 2024 Feb; 5(2):101412. PubMed ID: 38340723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CD4
    Longino NV; Yang J; Iyer JG; Ibrani D; Chow IT; Laing KJ; Campbell VL; Paulson KG; Kulikauskas RM; Church CD; James EA; Nghiem P; Kwok WW; Koelle DM
    Cancer Immunol Res; 2019 Oct; 7(10):1727-1739. PubMed ID: 31405946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
    Vandeven N; Nghiem P
    Immunotherapy; 2016 Jul; 8(8):907-21. PubMed ID: 27381685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Merkel cell polyomavirus-specific and CD39
    Ryu H; Bi TM; Pulliam TH; Sarkar K; Church CD; Kumar N; Mayer-Blackwell K; Jani S; Ramchurren N; Hansen UK; Hadrup SR; Fling SP; Koelle DM; Nghiem P; Newell EW
    Cell Rep Med; 2024 Feb; 5(2):101390. PubMed ID: 38340724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.
    Spassova I; Ugurel S; Kubat L; Zimmer L; Terheyden P; Mohr A; Björn Andtback H; Villabona L; Leiter U; Eigentler T; Loquai C; Hassel JC; Gambichler T; Haferkamp S; Mohr P; Pfoehler C; Heinzerling L; Gutzmer R; Utikal JS; Horny K; Schildhaus HU; Habermann D; Hoffmann D; Schadendorf D; Becker JC
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors.
    Lyngaa R; Pedersen NW; Schrama D; Thrue CA; Ibrani D; Met O; Thor Straten P; Nghiem P; Becker JC; Hadrup SR
    Clin Cancer Res; 2014 Apr; 20(7):1768-78. PubMed ID: 24526738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Merkel-cell carcinoma].
    Moll I
    Pathologe; 2019 Dec; 40(Suppl 3):350-354. PubMed ID: 31820040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.